日本の慢性排菌結核患者におけるＭＤＲ‐ＴＢ・ＸＤＲ‐ＴＢの薬剤感受性試験結果

• 鹿住 祐子

  結核予防会結核研究所

• 板垣 信則

  結核予防会結核研究所

• 大森 正子

  結核予防会結核研究所

• 和田 雅子

  結核予防会結核研究所

• 星野 斉之

  結核予防会結核研究所

• 御手洗 聡

  結核予防会結核研究所

• 菅原 勇

  結核予防会結核研究所

• 石川 信克

  結核予防会結核研究所

• 森 亨

  国立感染症研究所ハンセン病研究センター

書誌事項

タイトル別名

• FREQUENCY OF MDR-TB/XDR-TB STRAINS ISOLATED FROM CHRONIC PULMONARY TUBERCULOSIS PATIENTS IN JAPAN
• ニホン ノ マンセイ ハイキン ケッカク カンジャ ニ オケル MDR TB XDR TB ノ ヤクザイ カンジュセイ シケン ケッカ

抄録

[Purpose] To observe the frequency of MDR-TB/XDR-TB strains isolated from chronic pulmonary tuberculosis patients in Japan.<BR>[Object] Ad hoc National Tuberculosis Survey 2000 on frequency of MDR-TB and XDR-TB strains.<BR>[Materials and method] Four hundre d and thirty four clinical isolates were collected by the Ad hoc National Tuberculosis Survey 2000, the drug susceptibility testings (proportion method, MGIT Middlebrook, and BrothMlC NTM) were conducted on these strains. These clinical isolates were obtained from patients registered at Health Centers in Japan by the end of 1999 who were culture-positive in 1999 and were registered before January 1st, 1 998. The isolates used in this study were selected from patients who were culturepositive at shortest 2 years after the registration.<BR>[Result] The clinical isolates resis tant to both I NH and RFP were 321 out of 434 (74.0%). The 180 MDR-resistant clinical isolates were also resistant to levofloxacin and amikacin and/or kanamycin. These phenotypes are XDR-TB. No previously registered cases were 165, and previously registered cases were 143 and unknown cases were 13 out of 321 MDR-TB. In 180 XDR-TB cases, no previously registered cases were 95, previously registered cases were 78 and unknown cases were 7. In no previously registered cases, more than 50%cases started treatment in 1990s. Approximately 50% of previously registered patients started treatment in 1960s and 1970s.<BR>[Conclusion] We performed drug susceptibility testing for 434 clinical isolates which were culture-positive at shortest 2 years after registration. No. of MDR-TB patients was 321and that of XDR-TB patients was 180. The treatment outcome of these patients have to be followed up carefully at Health Centers. The frequency of amikacin resistance was relatively high. This may be due to either common use of amikacin or cross-resistance against streptomycin and kanamycin.

収録刊行物

• 結核

  結核 82 (12), 891-896, 2007

  一般社団法人 日本結核病学会

キーワード

• 多剤耐性結核菌(MDR-TB)
• 超多剤耐性結核菌(XDR-TB)
• 全国実態調査
• 交差耐性

詳細情報

• CRID: 1390282679976342016
• NII論文ID: 10025687994
• NII書誌ID: AN00073442
• DOI: 10.11400/kekkaku1923.82.891
• ISSN: 18842410
• ISSN: 00229776
• NDL書誌ID: 9309026
• Web Site: https://ndlsearch.ndl.go.jp/books/R000000004-I9309026
• Web Site: https://search.jamas.or.jp/link/ui/2008118576
• 本文言語コード: ja
• データソース種別:
  • JaLC
  • NDL
  • CiNii Articles
• 抄録ライセンスフラグ: 使用不可